Chinese biotech sector faces funding headwinds as global pharmaceutical deal-making slows

Chinese biotech firms have increasingly relied on cross-border out-licensing deals to achieve profitability as traditional IPO funding channels have dried up. Multinational pharmaceutical companies are now signaling budget constraints, threatening the sustainability of this primary capital source for Chinese drug developers.